替吉奥与奥沙利铂同步放化疗对转移性三阴乳腺癌患者预后生存质量的影响

Effect of Gio Synchronized with Oxaliplatin Chemotherapy in Metastatic Triple-negative Breast Cancer Patient Survival Quality

本研究为观察分析替吉奥与奥沙利铂同步放化疗对转移性三阴乳腺癌患者预后生存质量的影响。将42例转移性三阴乳腺癌患者进行研究,按照随机数表法将所收治的患者分为治疗组21例和对照组21例。对照组予以静脉滴注130 mg/m^2奥沙利铂,第1天且静脉滴注持续2 h。治疗组在此基础上予以口服60 mg/m^2替吉奥,第1~14天,早晚各1次。2组患者1个疗程均为2周,共治疗2个疗程。观察并比较两组患者治疗后临床疗效、相关毒副作用、远期生存情况以及预后生存质量情况。通关相关分析表明治疗后,治疗组的临床有效率(57.14%)与对照组的临床有效率(23.81%)相比,差异有明显统计学意义(p<0.05)。治疗组患者在心理状态、家务活动、家庭关系和工作及经济情况的评分均高于对照组患者,差异具有明显统计学意义(p<0.05)。治疗组不良反应发生率(23.81%)与对照组不良反应发生率(66.67%)相比,差异具有统计学意义(p<0.05)。研究结果表明,替吉奥与奥沙利铂同步放化疗方案治疗转移性三阴乳腺癌临床治疗效果显著,显著提高患者远期生存情况和生存质量,且患者的毒副作用可耐受,值得在临床上推广使用。

To study the effect of Gio synchronized with Oxaliplatin chemotherapy in metastatic triple-negative breast cancer patient survival quality. 42 cases with metastatic triple-negative breast cancer from the period of February 2015 to February 2016 in our hospital were studied. According to the random number table, they were divided into treatment group （n=21） and control group （n=21）. Control group was treated intravenous infusion of 130 mg/m^2Oxaliplatin, intravenous infusion on day 1 and continued 2 h. The treatment group was given oral 60 mg/m^2 on the basis ofGio, 1 to 14 days, twice daily. Two groups a course for two weeks, a total of 2 courses of treatment. They were compared with clinical efficacy related side effects, long-term survival and quality of patient survival situation. The analysis showed after treatment, the total effective rate of the treatment group （57.14%） compared with the control group （23.81%）, the difference was statistically significant （/9〈0.05）. In mental status, household activities, work and family relationships and economic conditions scores, treatment group was higher than the control group, the difference was statistically significant （p 〈0.05）. The adverse reaction rate of treatment group （23.81%） compared with the control group （66.67%）, the difference was statistically significant （p 〈0.05）. The result showed that Gio concurrent chemotherapy with Oxaliplatin treatment of metastatic triple-negative breast cancer treatment was significant, long-term survival and quality of life of patients was significantly improved, and patients can tolerate the side effects. It should be introduced in clinical practice.